{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:57:15Z","timestamp":1790351835590,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) can be late complications following mutagenic treatment. Limited data is available on the outcome of patients developing therapy-related MDS and AML after treatment for multiple myeloma (MM). We identified 250 patients with therapy-associated MDS or AML in the Duesseldorf MDS registry. Of those, 50 patients were previously diagnosed with multiple myeloma (mm-MDS\/AML). We compared them to patients with de novo MDS (<jats:italic>n<\/jats:italic>\u2009=\u20094862) and to patients with MDS following other underlying diseases (tMDS) (<jats:italic>n<\/jats:italic>\u2009=\u2009200). mm-MDS patients and tMDS patients showed similar karyotypes and degrees of cytopenia. However, mm-MDS patients had significantly higher blast counts and more often belonged to the high-risk group according to the International Prognostic Scoring System (IPSS) (both<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Although the rate of progression to AML was similar in mm-MDS and tMDS, both transformed significantly more often than de novo MDS (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Median overall survival of patients with mm-MDS (13\u00a0months; range: 1\u201399) and tMDS (13\u00a0months; range 0\u2013160) was also similar yet significantly shorter than patients with de novo MDS (32\u00a0months; range 0\u2013345\u00a0months; p\u2009&lt;\u20090.05). Furthermore, survival of mm-MDS patients was not affected by myeloma activity. Despite significantly more high-risk disease and higher blast cell counts, myeloma-associated MDS-patients show features akin to other tMDS. Survival is similar to other tMDS and irrespective of myeloma remission status or transformation to AML. Thus, patient outcome is not determined by competing clones but rather by MDS governing the stem cell niche.<\/jats:p>","DOI":"10.1007\/s00277-022-04775-1","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T05:02:35Z","timestamp":1646802155000},"page":"1031-1038","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Therapy-related myeloid neoplasms following treatment for multiple myeloma\u2014a single center analysis"],"prefix":"10.1007","volume":"101","author":[{"given":"A.","family":"Boquoi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. M.","family":"Banahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mohring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Savickaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Strapatsas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Hildebrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Kobbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Gattermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Germing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Fenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,9]]},"reference":[{"issue":"20","key":"4775_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"issue":"10","key":"4775_CR2","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.3324\/haematol.11034","volume":"92","author":"G Leone","year":"2007","unstructured":"Leone G, Pagano L, Ben-Yehuda D, Voso MT (2007) Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 92(10):1389\u20131398","journal-title":"Haematologica"},{"issue":"5","key":"4775_CR3","first-page":"691","volume":"90","author":"S Knipp","year":"2005","unstructured":"Knipp S, Hildebrandt B, Richter J, Haas R, Germing U, Gattermann N (2005) Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7. Haematologica 90(5):691\u2013693","journal-title":"Haematologica"},{"issue":"3","key":"4775_CR4","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1182\/blood-2003-11-3938","volume":"104","author":"J Offman","year":"2004","unstructured":"Offman J, Opelz G, Doehler B, Cummins D, Halil O, Banner NR et al (2004) Defective DNA mismatch repair in acute myeloid leukemia\/myelodysplastic syndrome after organ transplantation. Blood 104(3):822\u2013828","journal-title":"Blood"},{"issue":"2","key":"4775_CR5","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3324\/haematol.2011.049114","volume":"97","author":"T Schroeder","year":"2012","unstructured":"Schroeder T, Kuendgen A, Kayser S et al (2012) Therapy-related myeloid neoplasms following treatment with radioiodine. Haematologica 97(2):206\u2013212. https:\/\/doi.org\/10.3324\/haematol.2011.049114","journal-title":"Haematologica"},{"issue":"2","key":"4775_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/MOH.0b013e328343997a","volume":"18","author":"R Bhatia","year":"2011","unstructured":"Bhatia R, Deeg HJ (2011) Treatment-Related Myelodysplastic Syndrome \u2013 Molecular Characteristics and Therapy. Curr Opin Hematol 18(2):77\u201382","journal-title":"Curr Opin Hematol"},{"issue":"4","key":"4775_CR7","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1053\/j.seminoncol.2008.04.012","volume":"35","author":"LA Godley","year":"2008","unstructured":"Godley LA, Larson RA (2008) Therapy-related myeloid leukemia. Semin Oncol 35(4):418\u2013429","journal-title":"Semin Oncol"},{"issue":"1","key":"4775_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1182\/blood-2002-11-3343","volume":"102","author":"SM Smith","year":"2003","unstructured":"Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J et al (2003) Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 102(1):43\u201352","journal-title":"Blood"},{"key":"4775_CR9","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3324\/haematol.2008.005157","volume":"94","author":"RA Larson","year":"2009","unstructured":"Larson RA (2009) Therapy-related myeloid neoplasms. Haematologica 94:454\u2013459. https:\/\/doi.org\/10.3324\/haematol.2008.005157","journal-title":"Haematologica"},{"issue":"12","key":"4775_CR10","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/j.leukres.2011.06.001","volume":"35","author":"J Neukirchen","year":"2011","unstructured":"Neukirchen J, Schoonen WM, Strupp C, Gattermann N, Aul C, Haas R, Germing U (2011) Incidence and prevalence of myelodysplastic syndromes: data from the D\u00fcsseldorf MDS-registry. Leuk Res 35(12):1591\u20131596. https:\/\/doi.org\/10.1016\/j.leukres.2011.06.001","journal-title":"Leuk Res"},{"issue":"3","key":"4775_CR11","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41375-020-0917-7","volume":"35","author":"A Kuendgen","year":"2021","unstructured":"Kuendgen A, Nomdedeu M, Tuechler H, Garcia-Manero G, Komrokji RS, Sekeres MA, Della Porta MG, Cazzola M, DeZern AE, Roboz GJ, Steensma DP, Van de Loosdrecht AA, Schlenk RF, Grau J, Calvo X, Blum S, Pereira A, Valent P, Costa D, Giagounidis A, Xicoy B, D\u00f6hner H, Platzbecker U, Pedro C, L\u00fcbbert M, Oiartzabal I, D\u00edez-Campelo M, Cedena MT, Machherndl-Spandl S, L\u00f3pez-Pav\u00eda M, Baldus CD, Martinez-de-Sola M, Stauder R, Merchan B, List A, Ganster C, Schroeder T, Voso MT, Pfeilst\u00f6cker M, Sill H, Hildebrandt B, Esteve J, Nomdedeu B, Cobo F, Haas R, Sole F, Germing U, Greenberg PL, Haase D, Sanz G (2021) Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. Leukemia 35(3):835\u2013849. https:\/\/doi.org\/10.1038\/s41375-020-0917-7","journal-title":"Leukemia"},{"issue":"3","key":"4775_CR12","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","volume":"115","author":"H D\u00f6hner","year":"2010","unstructured":"D\u00f6hner H, Estey EH, Amadori S, Appelbaum FR, B\u00fcchner T, Burnett AK et al (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115(3):453\u2013474","journal-title":"Blood"},{"issue":"9","key":"4775_CR13","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1001\/jama.1969.03160090040009","volume":"208","author":"R Alexanian","year":"1969","unstructured":"Alexanian R, Haut A, Khan AU et al (1969) Treatment for Multiple Myeloma: Combination Chemotherapy With Different Melphalan Dose Regimens. JAMA 208(9):1680\u20131685. https:\/\/doi.org\/10.1001\/jama.1969.03160090040009","journal-title":"JAMA"},{"issue":"4","key":"4775_CR14","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, L\u00f6wenberg B, Bloomfield CD (2017) Diagnosis and management of AML in adults\u202f: 2017 ELN recommendations from an international expert panel. Blood 129(4):424\u2013447. https:\/\/doi.org\/10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"key":"4775_CR15","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T et al (2012) Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 366:1782\u20131791","journal-title":"N Engl J Med"},{"key":"4775_CR16","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","volume":"366","author":"A Palumbo","year":"2012","unstructured":"Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J et al (2012) Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 366:1759\u20131769","journal-title":"N Engl J Med"},{"key":"4775_CR17","doi-asserted-by":"publisher","first-page":"100757","DOI":"10.1016\/j.blre.2020.100757","volume":"46","author":"C Poh","year":"2021","unstructured":"Poh C, Keegan T, Rosenberg AS (2021) Second primary malignancies in multiple myeloma: A review. Blood Rev 46:100757. https:\/\/doi.org\/10.1016\/j.blre.2020.100757","journal-title":"Blood Rev"},{"issue":"3","key":"4775_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S1470-2045(13)70609-0","volume":"15","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A, Larocca A et al (2014) Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol 15(3):333\u2013342","journal-title":"Lancet Oncol"},{"issue":"4","key":"4775_CR19","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1093\/annonc\/mdx160","volume":"29","author":"P Musto","year":"2018","unstructured":"Musto P, Anderson KC, Attal M, Richardson PG, Badros A, Hou J, Comenzo R, Du J, Durie BGM, San Miguel J, Einsele H, Chen WM, Garderet L, Pietrantuono G, Hillengass J, Kyle RA, Moreau P, Lahuerta JJ, Landgren O, Ludwig H, Larocca A, Mahindra A, Cavo M, Mazumder A, McCarthy PL, Nouel A, Rajkumar SV, Reiman A, Riva E, Sezer O, Terpos E, Turesson I, Usmani S, Weiss BM, Palumbo A, International MyelomaWorking Group (2018) Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol. 29(4):1074. https:\/\/doi.org\/10.1093\/annonc\/mdx160 (Erratum for: Ann Oncol. 2017;28(2):228-245)","journal-title":"Ann Oncol."},{"issue":"7","key":"4775_CR20","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","volume":"117","author":"S Kayser","year":"2011","unstructured":"Kayser S, D\u00f6hner K, Krauter J, K\u00f6hne CH, Horst HA, Held G, von Lilienfeld-Toal M, Wilhelm S, K\u00fcndgen A, G\u00f6tze K, Rummel M, Nachbaur D, Schlegelberger B, G\u00f6hring G, Sp\u00e4th D, Morlok C, Zucknick M, Ganser A, D\u00f6hner H, Schlenk RF, German-Austrian AMLSG (2011) The impact of therapy-related acute myeloid leukemia (AML) on outcome on 2853 adult patients with newly diagnosed AML. Blood. 117(7):2137\u201345. https:\/\/doi.org\/10.1182\/blood-2010-08-301713","journal-title":"Blood."},{"issue":"13","key":"4775_CR21","doi-asserted-by":"publisher","first-page":"4385","DOI":"10.1182\/blood-2007-03-082404","volume":"110","author":"D Haase","year":"2007","unstructured":"Haase D, Germing U, Schanz J, Pfeilst\u00f6cker M, N\u00f6sslinger T, Hildebrandt B, K\u00fcndgen A, L\u00fcbbert M, Kunzmann R, Giagounidis AA, Aul C, Tr\u00fcmper L, Krieger O, Stauder R, M\u00fcller TH, Wimazal F, Valent P, Fonatsch C, Steidl C (2007) New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes\u202f: evidence from a core dataset of 2124 patients. Blood 110(13):4385\u20134395","journal-title":"Blood"},{"issue":"1","key":"4775_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/0165-4608(94)00284-i","volume":"82","author":"JR Sawyer","year":"1995","unstructured":"Sawyer JR, Waldron JA, Jagannath S, Barlogie B (1995) Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 82(1):41\u201349. https:\/\/doi.org\/10.1016\/0165-4608(94)00284-i","journal-title":"Cancer Genet Cytogenet"},{"issue":"12","key":"4775_CR23","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/ajh.20998","volume":"82","author":"AN Mohamed","year":"2007","unstructured":"Mohamed AN, Bentley G, Bonnett ML, Zonder J, Al-Katib A (2007) Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes. Am J Hematol 82(12):1080\u20131087. https:\/\/doi.org\/10.1002\/ajh.20998","journal-title":"Am J Hematol"},{"issue":"1","key":"4775_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1182\/blood-2002-11-3343","volume":"102","author":"SM Smith","year":"2003","unstructured":"Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, Vardiman JW, Rowley JD, Larson RA (2003) Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 102(1):43\u201352","journal-title":"Blood"},{"issue":"6","key":"4775_CR25","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1309\/AJCPOP7APGDT9JIU","volume":"138","author":"DM Reddi","year":"2012","unstructured":"Reddi DM, Lu CM, Fedoriw G, Liu YC, Wang FF, Ely S, Boswell EL, Louissaint A Jr, Arcasoy MO, Goodman BK, Wang E (2012) Myeloid Neoplasms Secondary to Plasma Cell Myeloma: An Intrinsic Predisposition or Therapy-Related Phenomenon?: A Clinicopathologic Study of 41 Cases and Correlation of Cytogenetic Features With Treatment Regimens. Am J Clin Pathol 138(6):855\u2013866","journal-title":"Am J Clin Pathol"},{"key":"4775_CR26","first-page":"4507","volume":"32","author":"S Chakraborty","year":"2012","unstructured":"Chakraborty S, Hauke RJ, Bonthu N, Tarantolo SR (2012) Increased incidence of a second lymphoproliferative malignancy in patients with multiple myeloma\u2014a SEER based study. Anticancer Res 32:4507\u20134515","journal-title":"Anticancer Res"},{"key":"4775_CR27","first-page":"930","volume":"24","author":"F Sahebi","year":"2018","unstructured":"Sahebi F et al (2018) Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents. BBMT 24:930\u2013936","journal-title":"BBMT"},{"key":"4775_CR28","unstructured":"SEER Cancer Statistics Review 1975\u20132015 https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"4775_CR29","doi-asserted-by":"crossref","first-page":"e13050","DOI":"10.1111\/eci.13050","volume":"49","author":"M Fern\u00e1ndez-Caballero","year":"2019","unstructured":"Fern\u00e1ndez-Caballero M, Salmer\u00f3n D, Dolores Chirlaque M et al (2019) Increasing therapy-related myeloid neoplasms in multiple myeloma. Eur J Clin Invest. 49:e13050","journal-title":"Eur J Clin Invest."},{"key":"4775_CR30","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal M et al (2012) Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 366:1782\u20131791","journal-title":"N Engl J Med"},{"issue":"4","key":"4775_CR31","first-page":"738","volume":"21","author":"A Mahindra","year":"2015","unstructured":"Mahindra A et al (2015) New Cancers after Autotransplantation for Multiple Myeloma. BBMT 21(4):738\u2013745","journal-title":"BBMT"},{"issue":"1","key":"4775_CR32","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/sj.leu.2403187","volume":"18","author":"C Schoch","year":"2004","unstructured":"Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T (2004) Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 18(1):120\u2013125","journal-title":"Leukemia"},{"issue":"7","key":"4775_CR33","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","volume":"117","author":"S Kayser","year":"2011","unstructured":"Kayser S, D\u00f6hner K, Krauter J, K\u00f6hne CH, Horst HA, Held G et al (2011) The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 117(7):2137\u20132145","journal-title":"Blood"},{"issue":"13","key":"4775_CR34","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1182\/blood-2011-04-347484","volume":"120","author":"I Bruns","year":"2012","unstructured":"Bruns I et al (2012) Multiple myeloma-related deregulation of bone marrow-derived CD34+ hematopoietic stem and progenitor cells. Blood 120(13):2620\u20132630","journal-title":"Blood"},{"issue":"10","key":"4775_CR35","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.3324\/haematol.2012.064121","volume":"97","author":"S Matarraz","year":"2012","unstructured":"Matarraz S, Paiva B, Diez-Campelo M, Corral L, P\u00e9rez E, Mateos MV, Giraldo P, Hern\u00e1ndez MT, San Miguel JF, Orfao A (2012) Haematologica 97(10):1608\u20131611. https:\/\/doi.org\/10.3324\/haematol.2012.064121","journal-title":"Haematologica"},{"issue":"15","key":"4775_CR36","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1182\/blood-2011-05-355743","volume":"118","author":"S Mailankody","year":"2011","unstructured":"Mailankody S, Pfeiffer RM, Kristinsson SY et al (2011) Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood 118(15):4086\u20134092. https:\/\/doi.org\/10.1182\/blood-2011-05-355743","journal-title":"Blood"},{"issue":"26","key":"4775_CR37","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood.2019003382","volume":"135","author":"C Maia","year":"2020","unstructured":"Maia C, Puig N, Cedena MT et al (2020) Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma. Blood 135(26):2375\u20132387","journal-title":"Blood"},{"issue":"22","key":"4775_CR38","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1182\/blood.V128.22.375.375","volume":"128","author":"B Paiva","year":"2016","unstructured":"Paiva B, Puig N, Cedena MT et al (2016) The Presence of MDS-like Phenotypic Abnormalities (MDS-PA) Identifies Newly Diagnosed Multiple Myeloma (MM) Patients with MDS\/AML-Related Somatic Mutations and Inferior Survival. Blood 128(22):375","journal-title":"Blood"},{"issue":"Supplement 1","key":"4775_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2020-136907","volume":"136","author":"F Gay","year":"2020","unstructured":"Gay F, Musto P, Rota Scalabrini D, Galli M, Belotti A, Zamagni E, Bertamini L, Zambello R, Quaresima M, De Sabbata G, Pietrantuono G, D\u2019Agostino M, Oddolo D, Capra A, Liberati AM, Palmieri S, Narni F, Offidani M, Cavo M, Boccadoro M (2020) Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial. Blood 136(Supplement 1):35\u201337. https:\/\/doi.org\/10.1182\/blood-2020-136907","journal-title":"Blood"},{"issue":"10218","key":"4775_CR40","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","volume":"395","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Krevvata M, Chen Y, Wang J, Kudva A, Ukropec J, Wroblewski S, Qi M, Kobos R, San-Miguel J (2020) Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet 395(10218):132\u2013141. https:\/\/doi.org\/10.1016\/S0140-6736(19)32956-3","journal-title":"Lancet"},{"issue":"2","key":"4775_CR41","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.clml.2014.07.001","volume":"15","author":"N Pemmaraju","year":"2015","unstructured":"Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras Gonz\u00e1lez GM, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K, Daver N, Nazha A, Verstovsek S, Jabbour E, De Lima M, Champlin R, Cortes J, Qazilbash MH (2015) Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 15(2):110\u2013114. https:\/\/doi.org\/10.1016\/j.clml.2014.07.001","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04775-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04775-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04775-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T15:58:55Z","timestamp":1700323135000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04775-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,9]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["4775"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04775-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,9]]},"assertion":[{"value":"23 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}